XERS Xeris Pharmaceuticals Inc.

9.01
+0.01  (+0%)
Previous Close 9
Open 8.92
Price To Book 3.25
Market Cap 243,156,033
Shares 26,987,351
Volume 166,472
Short Ratio
Av. Daily Volume 186,063
Stock charts supplied by TradingView

NewsSee all news

  1. Xeris Pharmaceuticals Appoints Mark Thierer to Board of Directors

    CHICAGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use

  2. Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    CHICAGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable

  3. Xeris Pharmaceuticals Begins Dosing Patients in a Phase 2 Clinical Trial Evaluating Its Novel Fixed-Ratio Co-Formulation of Pramlintide-Insulin for Diabetes

    Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,

  4. Xeris Pharmaceuticals Announces Expanded $85 Million Debt Facility With Oxford Finance and Silicon Valley Bank

    Provides up to three years of interest only and extension of maturity date Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop

  5. Xeris Pharmaceuticals Receives U.S. FDA Approval for GVOKE™ (glucagon), the First Ready-to-use Stable Liquid Glucagon for Severe Hypoglycemia

    First approval for Xeris is based on positive efficacy and safety results from multiple clinical studies GVOKE is the first premixed, prefilled, premeasured liquid glucagon offering ease of use for pediatric and adult

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2a data due 2H 2019.
Continuous glucagon
Hypoglycemia-Associated Autonomic Failure
Phase 3 trial to be initiated 2H 2019.
Continuous glucagon
Congenital Hyperinsulinism
Phase 2 data due 2H 2019.
Self administered glucagon
Exercise-Induced Hypoglycemia
Phase 2b data due 2H 2019.
Self administered glucagon
Post-Bariatric Hypoglycemia
FDA Approval announced September 10, 2019.
Glucagon Rescue Pen
Severe hypoglycemia
Phase 2 trial to be initiated 2H 2019.
Diazepam
Seizures
Phase 2 data due 1H 2020.
Pramlintide and insulin
Type 1 diabetes

Latest News

  1. Xeris Pharmaceuticals Appoints Mark Thierer to Board of Directors

    CHICAGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use

  2. Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    CHICAGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable

  3. Xeris Pharmaceuticals Begins Dosing Patients in a Phase 2 Clinical Trial Evaluating Its Novel Fixed-Ratio Co-Formulation of Pramlintide-Insulin for Diabetes

    Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,

  4. Xeris Pharmaceuticals Announces Expanded $85 Million Debt Facility With Oxford Finance and Silicon Valley Bank

    Provides up to three years of interest only and extension of maturity date Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop

  5. Xeris Pharmaceuticals Receives U.S. FDA Approval for GVOKE™ (glucagon), the First Ready-to-use Stable Liquid Glucagon for Severe Hypoglycemia

    First approval for Xeris is based on positive efficacy and safety results from multiple clinical studies GVOKE is the first premixed, prefilled, premeasured liquid glucagon offering ease of use for pediatric and adult

  6. Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

    CHICAGO, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable

  7. Xeris Pharmaceuticals to Present at Two September Healthcare Conferences

    CHICAGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use